Dana-Farber Cancer Institute Harvard University

Boston, Massachusetts

We've found

1 trials

at this facility

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Boston, MA

Use our guide to learn which trials are right for you!